Allscripts (NASDAQ: MDRX) reported Q4 EPS of $0.79, $0.54 better than the analyst estimate of $0.25. Revenue for the quarter came in at $392 million versus the consensus estimate of $386.75 million.

GUIDANCE:

For the full year 2022, Allscripts currently expects to achieve:

• Consolidated free cash flow from continuing operations between $165 million and $175 million
• Consolidated revenue growth of 1% to 2%

For earnings history and earnings-related data on Allscripts (MDRX) click here.